Clinical review: Topical ophthalmic use of cyclosporin A

Canan Asli Utine, Michael Stern, Esen K. Akpek

Research output: Contribution to journalReview articlepeer-review


Cyclosporine A (CsA) is an immunomodulatory agent that primarily inhibits the proliferation and action of T cells. Systemic CsA has been used successfully in solid organ transplantation and noninfectious uveitis. Topical CsA with various formulations has been used in the field of ocular surface diseases since early 1980s. An ophthalmic emulsion 0.05% (Restasis, Allergan, Irvine, CA), was approved by the United States Food and Drug Administration in 2003 to treat dry eye syndrome. This article aims to evaluate the peer-reviewed published scientific literature and to define well-established uses of CsA eyedrops in the field of ocular surface diseases.

Original languageEnglish (US)
Pages (from-to)352-361
Number of pages10
JournalOcular Immunology and Inflammation
Issue number5
StatePublished - Oct 1 2010


  • Atopic keratoconjunctivitis
  • Blepharitis
  • Cyclosporine A
  • Dry eye syndrome
  • Vernal keratoconjunctivitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology


Dive into the research topics of 'Clinical review: Topical ophthalmic use of cyclosporin A'. Together they form a unique fingerprint.

Cite this